CBIO FY 2025 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M

Gross Profit

$11M99.2% margin

Operating Income

-$153M-1407.5% margin

Net Income

-$150M-1382.7% margin

EPS (Diluted)

$-14.78

Cash Flow

Operating Cash Flow

-$72M

Free Cash Flow

-$72M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$240M

Total Liabilities

$37M

Stockholders' Equity

$203M

Cash & Equivalents

$213M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$0	—
Gross Profit	$11M	-$35,174	+30690.8%
Operating Income	-$153M	-$69M	-122.0%
Net Income	-$150M	-$71M	-109.8%